Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review (Q38441017)

3 September 2017

1 reference

title

Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review (English)

1 reference

3 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

10 June 2020

Luca D'Onofrio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

10 June 2020

Richard Eastell

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

10 June 2020

Paolo Pozzilli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

10 June 2020

Nicola Napoli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

10 June 2020

4

A V Schwartz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

25 April 2015

1 reference

Osteoporosis International

3 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

10 June 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

10 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

2073-2089

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25910746 AND SRC:MED&resulttype=core&format=json

Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EF

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

In vivo assessment of bone quality in postmenopausal women with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

FRAX underestimates fracture risk in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Pentosidine and increased fracture risk in older adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Trabecular bone score as an indicator for skeletal deterioration in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Metformin reverses the deleterious effects of high glucose on osteoblast function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Osteoblast differentiation is functionally associated with decreased AMP kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

AICAR, a small chemical molecule, primes osteogenic differentiation of adult mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Fracture risk in type 2 diabetes: update of a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

A cohort study of thiazolidinediones and fractures in older adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Fracture risk in diabetic elderly men: the MrOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Treatment effects on measures of body composition in the TODAY clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Extrapancreatic roles of glimepiride on osteoblasts from rat manibular bone in vitro: Regulation of cytodifferentiation through PI3-kinases/Akt signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Thiazolidinediones and fractures in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

PPARγ signaling and metabolism: the good, the bad and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effect of pioglitazone on transdifferentiation of preosteoblasts from rat bone mesenchymal stem cells into adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

IGF-1 and bone: New discoveries from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

PPAR-gamma regulates osteoclastogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Thiazolidinediones and fracture risk in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Use of thiazolidinediones and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Thiazolidinediones and fractures: evidence from translating research into action for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Thiazolidinedione use and the risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Risk of fracture with thiazolidinediones: disease or drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve ty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Ex vivo bone mineral density of the wrist: influence of medullar fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Receptors and effects of gut hormones in three osteoblastic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Differential Effects of PPAR-γ Activation versus Chemical or Genetic Reduction of DPP-4 Activity on Bone Quality in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Role of gastrointestinal hormones in postprandial reduction of bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Possible adverse effects of SGLT2 inhibitors on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Disassociation of bone resorption and formation by GLP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Four-month treatment with GLP-2 significantly increases hip BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-015-3123-0

Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

21 January 2018

1 reference

12 December 2020

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

1 reference

12 December 2020

Thiazolidinediones (TZDs) affect osteoblast viability and biomarkers independently of the TZD effects on aromatase

1 reference

12 December 2020

Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men

1 reference

12 December 2020

Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow

1 reference

12 December 2020

Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells

1 reference

12 December 2020

Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy

1 reference

12 December 2020

PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity

1 reference

12 December 2020

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus

1 reference

12 December 2020

GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia

1 reference

12 December 2020

DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats

1 reference

12 December 2020

The effects of pioglitazone on biochemical markers of bone turnover in the patients with type 2 diabetes.

1 reference

12 December 2020

A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes

1 reference

12 December 2020

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

1 reference

12 December 2020

Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial

1 reference

12 December 2020

Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients

1 reference

12 December 2020

Risk factors for fractures and falls in older women with type 2 diabetes mellitus

1 reference

12 December 2020

Distal upper and lower limb fractures associated with thiazolidinedione use.

1 reference

12 December 2020

Rosiglitazone decreases bone mass and bone marrow fat

1 reference

12 December 2020

The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study

1 reference

12 December 2020

Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women

1 reference

12 December 2020

Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin

1 reference

12 December 2020

Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats

1 reference

12 December 2020

Protective effect of metformin on periapical lesions in rats by decreasing the ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin

1 reference

12 December 2020

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus

1 reference

12 December 2020